Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 27, 2021 / 05:20PM GMT
Release Date Price: R$24.44 (+0.78%)
Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Director of Equity Research & Head of Healthcare Research

Hey, everybody. It's Alethia Young here. I cover large-cap, small, mid-cap at Cantor, biotech, of course. Very happy to have Sarepta Therapeutics. I have Doug Ingram, who's the President and CEO and Ian Estepan, who's the EVP and CFO. So obviously, you guys issued a press release this morning on 5051, so it was exciting to me at least. So let's start with that. Just give us the highlights of that release. And then, it also just seems like maybe a positive on the faster pathway to market and it seems like it was a little bit ahead of what I thought was the scheduled time for this. So maybe we start with there?

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Sure, Alethia. First, thank you for having us today. We're really excited to talk about the progress we're making. And we are also very excited about that press release this morning. I think I've said before, this broad strokes, we have been -- while

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot